.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,476,010

« Back to Dashboard

Claims for Patent: 8,476,010

Title:Propofol formulations with non-reactive container closures
Abstract: A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, optionally albumin, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.
Inventor(s): Desai; Neil P. (Pacific Palisades, CA), Yang; Andrew (Rosemead, CA), Ci; Sherry Xiaopei (San Marino, CA)
Assignee: APP Pharmaceuticals LLC (Schaumburg, IL)
Application Number:10/616,709
Patent Claims: 1. A sterile pharmaceutical composition of propofol in a container, comprising: a container which includes a closure and a composition in the container, and the composition in the container comprising from 0.5% to 10% by weight propofol and from about 0 to about 10% by weight solvent for propofol, where when the composition in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least 93% of the starting concentration (w/v) of the propofol; where the closure is selected from the group consisting of siliconized bromobutyl rubber, metal, and siliconized chlorobutyl rubber.

2. The sterile pharmaceutical composition in a container according to claim 1, the composition further comprising an aqueous phase and protein.

3. The sterile pharmaceutical composition in a container according to claim 2, wherein the protein is albumin.

4. The sterile pharmaceutical composition in a container according to claim 3, wherein the albumin is present in an amount of from about 0.01% to about 5% by weight of the composition.

5. The sterile pharmaceutical composition in a container according to claim 3, wherein the pH modifier is sodium hydroxide.

6. The sterile pharmaceutical composition in a container according to claim 2, wherein the aqueous phase comprises water for injection and a pH modifier.

7. The sterile pharmaceutical composition in a container according to claim 2, wherein the composition comprises a tonicity agent.

8. The sterile pharmaceutical composition in a container according to claim 7, wherein the tonicity agent is glycerin.

9. The sterile pharmaceutical composition in a container according to claim 2, wherein the composition further comprises a surfactant.

10. The sterile pharmaceutical composition in a container according to claim 9, wherein the surfactant is selected from the group consisting of phosphatides, synthetic phospholipids, natural phospholipids, lecithins, ethoxylated ethers and esters, tocopherol polyethylene glycol stearate, polypropylene-polyethylene block co-polymers, polyvinyl pyrrolidone, and polyvinylalcohol and combinations thereof.

11. The sterile pharmaceutical composition in a container according to claim 10, wherein the surfactant is selected from the group consisting of egg phosphatides, soya phosphatides, egg lecithins, soya lecithins, and combinations thereof.

12. The sterile pharmaceutical composition in a container according to claim 11, wherein the surfactant is egg lecithin.

13. The sterile pharmaceutical composition in a container according to claim 1 wherein the solvent is a water-immiscible solvent.

14. The sterile pharmaceutical composition in a container according to claim 13, wherein the water-immiscible solvent is selected from the group consisting of soybean, safflower, cottonseed, corn, coconut, sunflower, arachis, castor sesame, orange, limonene or olive oil, an ester of a medium or long-chain fatty acid, a chemically modified or manufactured palmitate, glyceral ester or polyoxyl, hydrogenated castor oil, a marine oil, fractionated oils, and mixtures thereof.

15. The sterile pharmaceutical composition in a container according to claim 14, wherein the water-immiscible solvent is soybean oil.

16. The sterile pharmaceutical composition in a container according to claim 1, wherein the solvent is selected from the group consisting of chloroform, methylene chloride, ethyl acetate, ethanol, tetrahydrofuran, dioxane, acetonitrile, acetone, dimethyl sulfoxide, dimethyl formamide, methyl pyrrolidinone, C1-C20 alcohols, C2-C20 esters, C3-C20 ketones, polyethylene glycols, aliphatic hydrocarbons, aromatic hydrocarbons, halogenated hydrocarbons and combinations thereof.

17. The sterile pharmaceutical composition in a container according to claim 1, wherein the closure is coated with a material inert to propofol.

18. The sterile pharmaceutical composition in a container according to claim 1, wherein the closure consists essentially of a material that is itself inert to propofol.

19. The sterile pharmaceutical composition in a container according to claim 18, wherein the closure material is metal.

20. The sterile pharmaceutical composition in a container according to claim 1, wherein the closure comprises siliconized bromobutyl rubber.

21. The sterile pharmaceutical composition in a container according to claim 1, wherein the closure comprises metal.

22. The sterile pharmaceutical composition in a container according to claim 1, wherein the closure comprises siliconized chlorobutyl rubber.

23. The sterile pharmaceutical composition in a container according to claim 1, wherein the composition comprises soybean oil in an amount of from about 0.5% to about 6% by weight of the composition, egg lecithin in an amount of from about 0.1% to about 5% by weight of the composition and human serum albumin in an amount of from about 0.1% to about 5% of the composition.

24. The sterile pharmaceutical composition in a container according to claim 1, wherein when the composition is stored in the container sealed with the closure for at least two months, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least about 95% of the starting concentration (w/v) of the propofol.

25. The sterile pharmaceutical composition in a container according to claim 24, wherein the composition is stored in the container sealed with the closure in a controlled environment of about 40.degree. C. and about 75% relative humidity for at least two months.

26. The sterile pharmaceutical composition in a container according to claim 1, where when the composition in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least 95% of the starting concentration (w/v) of the propofol.

27. The sterile pharmaceutical composition in a container according to claim 1, where when the composition in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least 97% of the starting concentration (w/v) of the propofol.

28. The sterile pharmaceutical composition in a container according to claim 1, where when the composition in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least 99% of the starting concentration (w/v) of the propofol.

29. The sterile pharmaceutical composition in a container according to claim 1, the composition comprising less than about 0.5% by weight solvent for propofol.

30. The sterile pharmaceutical composition in a container according to claim 1, the composition comprising from about 0.5% to about 6% by weight solvent for propofol.

31. The sterile pharmaceutical composition in a container according to claim 30, the composition comprising from about 3% to about 6% by weight solvent for propofol.

32. The sterile pharmaceutical composition in a container according to claim 31, the solvent comprising soybean oil.

33. A sterile pharmaceutical composition of propofol in a container, comprising: a container which includes a closure and an oil-in-water emulsion for parenteral administration of propofol in the container, the emulsion comprising an oil phase comprising propofol and a solvent for propofol, and an aqueous phase comprising water for injection, the emulsion comprising from about 0 to about 10% by weight of the solvent, the emulsion further comprising a stabilizing layer for the oil phase, the stabilizing layer comprising a surfactant and a protein; where when the emulsion in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the emulsion maintains a propofol concentration (w/v) measured by HPLC that is at least 93% of the starting concentration (w/v) of the propofol; where the closure is selected from the group consisting of siliconized bromobutyl rubber, metal, and siliconized chlorobutyl rubber.

34. The sterile pharmaceutical composition in a container according to claim 33, wherein the protein is selected from the group consisting of albumins, globulins, immunoglobulins, lipoproteins, caseins, insulins, hemoglobins, lysozymes, alpha-2-macroglobulin, fibronectins, vitronectins, fibrinogens, lipases, peptides, enzymes, antibodies and combinations thereof.

35. The sterile pharmaceutical composition in a container according to claim 33, wherein the surfactant is selected from the group consisting of phosphatides, synthetic phospholipids, natural phospholipids, lecithins, ethoxylated ethers and esters, tocopherol polyethylene glycol stearate, polypropylene-polyethylene block co-polymers, polyvinyl pyrrolidone, and polyvinylalcohol.

36. The sterile pharmaceutical composition in a container according to claim 35, comprising: a) about 1% to 2% by weight of propofol, b) 3-6% by weight of soybean oil, c) 0.2-1.0% by weight of egg lecithin, d) about 2.25% by weight of glycerin, e) sodium hydroxide, f) water to 100%, and g) pH between 5.0-8.5.

37. The sterile pharmaceutical composition in a container according to claim 33, wherein the oil phase is propofol neat.

38. The sterile pharmaceutical composition in a container according to claim 33, wherein the surfactant is lecithin and the protein is albumin.

39. The sterile pharmaceutical composition in a container according to claim 38, wherein the egg lecithin is present in the emulsion in an amount of from about 0.1% to about 5% by weight of the emulsion and the albumin is present in the emulsion in an amount of from about 0.01% to about 5% by weight of the emulsion.

40. The sterile pharmaceutical composition in a container according to claim 39, wherein the oil phase includes soybean oil.

41. The sterile pharmaceutical composition in a container according to claim 40, wherein the soybean oil is present in an amount of from about 0.5% to about 6% by weight of the emulsion.

42. The sterile pharmaceutical composition in a container according to claim 40, wherein the soybean oil is present in the emulsion in an amount of from about 0.5% to about 3% by weight of the emulsion.

43. The sterile pharmaceutical composition in a container according to claim 33, wherein the oil phase includes a solvent, and wherein the solvent is selected from the group consisting of soybean, safflower, cottonseed, corn, coconut, sunflower, arachis, castor sesame, orange, limonene or olive oil, an ester of a medium or long-chain fatty acid, a chemically modified or manufactured palmitate, glyceral ester or polyoxyl, hydrogenated castor oil, a marine oil, fractionated oils, and mixtures thereof, chloroform, methylene chloride, ethyl acetate, ethanol, tetrahydrofuran, dioxane, acetonitrile, acetone, dimethyl sulfoxide, dimethyl formamide, methyl pyrrolidinone, C1-C20 alcohols, C2-C20 esters, C3-C20 ketones, polyethylene glycols, aliphatic hydrocarbons, aromatic hydrocarbons, halogenated hydrocarbons and combinations thereof.

44. The sterile pharmaceutical composition in a container according to claim 43, wherein the solvent is soybean oil.

45. The sterile pharmaceutical composition in a container according to claim 44, wherein the soybean oil is present in an amount of from about 0.5% to about 6% by weight of the emulsion.

46. The sterile pharmaceutical composition in a container according to claim 33, wherein the closure is treated with a material inert to propofol.

47. The sterile pharmaceutical composition in a container according to claim 33, wherein the closure consists essentially of a material that is itself inert to propofol.

48. The sterile pharmaceutical composition in a container according to claim 47, wherein the closure material is metal.

49. The sterile pharmaceutical composition in a container according to claim 33, wherein the closure comprises siliconized bromobutyl rubber.

50. The sterile pharmaceutical composition in a container according to claim 33, wherein the closure comprises metal.

51. The sterile pharmaceutical composition in a container according to claim 33, wherein the closure comprises siliconized chlorobutyl rubber.

52. The sterile pharmaceutical composition in a container according to claim 33, where when the emulsion in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the emulsion maintains a propofol concentration (w/v) measured by HPLC that is at least 95% of the starting concentration (w/v) of the propofol.

53. The sterile pharmaceutical composition in a container according to claim 33, where when the emulsion in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the emulsion maintains a propofol concentration (w/v) measured by HPLC that is at least 97% of the starting concentration (w/v) of the propofol.

54. The sterile pharmaceutical composition in a container according to claim 33, where when the emulsion in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the emulsion maintains a propofol concentration (w/v) measured by HPLC that is at least 99% of the starting concentration (w/v) of the propofol.

55. The sterile pharmaceutical composition in a container according to claim 33, where when the emulsion is stored in the container sealed with the closure for at least two months, the emulsion maintains a propofol concentration (w/v) measured by HPLC that is at least 95% of the starting concentration (w/v) of the propofol.

56. The sterile pharmaceutical composition in a container according to claim 33, where when the emulsion is stored in the container sealed with the closure in a controlled environment of about 40.degree. C. and about 75% relative humidity for at least two months, the emulsion maintains a propofol concentration (w/v) measured by HPLC that is at least 95% of the starting concentration (w/v) of the propofol.

57. A sterile, injectable pharmaceutical composition in a container, comprising: a container which includes a closure and a composition in the container, the composition comprising a) microdroplets having a mean size of from about 20 nanometers to about 1000 nanometers, the microdroplets comprising a sphere of propofol surrounded by a stabilizing layer comprising a phospholipid and devoid of oils capable of supporting bacterial growth; and b) a pharmaceutically acceptable injectable carrier; where when the composition in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least 93% of the starting concentration (w/v) of the propofol; where the closure is selected from the group consisting of siliconized bromobutyl rubber, metal, and siliconized chlorobutyl rubber.

58. The sterile, injectable pharmaceutical composition in a container according to claim 57, wherein the composition further comprises albumin.

59. The sterile, injectable pharmaceutical composition in a container according to claim 57, wherein the stabilizing layer includes albumin.

60. The sterile, injectable pharmaceutical composition in a container according to claim 57, wherein the closure is coated with a material inert to propofol.

61. The sterile, injectable pharmaceutical composition in a container according to claim 57, wherein the closure consists essentially of a material that is itself inert to propofol.

62. The sterile, injectable pharmaceutical composition in a container according to claim 61, wherein the closure material is metal.

63. The sterile, injectable pharmaceutical composition in a container according to claim 57, wherein the closure comprises siliconized bromobutyl rubber.

64. The sterile, injectable pharmaceutical composition in a container according to claim 57, wherein the closure comprises metal.

65. The sterile, injectable pharmaceutical composition in a container according to claim 57, wherein the closure comprises siliconized chlorobutyl rubber.

66. The sterile, injectable pharmaceutical composition in a container according to claim 57, where when the composition in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least 95% of the starting concentration (w/v) of the propofol.

67. The sterile, injectable pharmaceutical composition in a container according to claim 57, where when the composition in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least 97% of the starting concentration (w/v) of the propofol.

68. The sterile, injectable pharmaceutical composition in a container according to claim 57, where when the composition in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least 99% of the starting concentration (w/v) of the propofol.

69. The sterile, injectable pharmaceutical composition in a container according to claim 57, where when the composition is stored in the container sealed with the closure for at least two months, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least 95% of the starting concentration (w/v) of the propofol.

70. The sterile, injectable pharmaceutical composition in a container according to claim 57, where when the composition is stored in the container sealed with the closure in a controlled environment of about 40.degree. C. and about 75% relative humidity for at least two months, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least 95% of the starting concentration (w/v) of the propofol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc